Bupropion

Sold as Wellbutrin xl, Voxra xl, Nicolift, Wepron sr, Dirento sr, Weldep xr, Budep xr, Bupropion xr adco, Prodyna xr, Bupropion xr DYNA, Bupropion accord, Bupropion 150xl DRL, Bupropion xl DRL, Bupropion xl AURO, Genipron xl

S5Read from the PI-PIL document and verified

C₁₃H₁₈ClNO239.74 g/mol

2-(tert-Butylamino)-1-(3-chlorophenyl)propan-1-one

Drag to rotate. Structure from PubChem CID 444.

Loading Wikipedia summary

Registration

Applicants: 10
Registrations: 23
Schedule source: SAHPRA documentation

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Glaxosmithkline South Africa (Pty) LimitedCertificate held by Glaxosmithkline South Africa (Pty) Ltd, Gsk	Wellbutrin xl, Voxra xl	150, 300	410371, 410372, 410373, 410374	S5	PI PIL
Acino Pharma (Pty) Ltd	Nicolift	Not stated	430448	S5	None
Ranbaxy (SA) (Pty) LtdCancelled	Wepron sr	150	430627	S5	None
Trinity Pharma (Pty) Ltd	Dirento sr	150 mg	450826	S5	None
Ranbaxy Pharmaceutical (Pty) Ltd	Weldep xr, Budep xr	150, 300	480112.114, 480113.115, 480114, 480115	S5	None
Adcock ingram limited	Bupropion xr adco	150 mg	500967.065	S5	PI PIL
Pharma Dynamics (Pty) Ltd2 of 4 cancelled	Prodyna xr, Bupropion xr DYNA	150 mg, 300 mg	540181, 540182, 540183.181, 540184.182	S5	None
Accord Healthcare (Pty) Ltd	Bupropion accord	300 mg	550778	S5	PI PIL
Dr Reddyæs Laboratories (Pty) Ltd	Bupropion 150xl DRL, Bupropion xl DRL	300	560292, 560293	S5	None
Aurogen South Africa (Pty) Ltd	Bupropion xl AURO, Genipron xl	150 mg, 300 mg	560751, 560752, 560753.751, 560754.752	S5	None

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Wellbutrin xl 150 EACH TABLET CONTAINS BUPROPION 150,0 mg	150Extended-release tablets	41037141/1.2/0371Approved 23 April 2024	Registered	S5	PI PIL
Wellbutrin xl 300 EACH TABLET CONTAINS BUPROPION 300,0 mg	300Extended-release tablets	41037241/1.2/0372Approved 23 April 2024	Registered	S5	PI PIL
Voxra xl 150 EACH TABLET CONTAINS BUPROPION 150,0 mg	150Tablet	41037341/1.2/0373Approved 23 April 2024	Registered	S5	PI PIL
Voxra xl 300 EACH TABLET CONTAINS BUPROPION 300,0 mg	300Tablet	41037441/1.2/0374Approved 23 April 2024	Registered	S5	PI PIL
Nicolift EACH TABLET CONTAINS BUPROPION 150,0 mg	Not listed	43044843/34/0448	Registered	S5	None
Wepron sr 150 EACH TABLET CONTAINS BUPROPION 150,0 mg	150	43062743/1.2/0627	Cancelled	S5	None
Dirento 150 MG sr EACH TABLET CONTAINS BUPROPION 150,0 mg	150 mg	45082645/1.2/0826	Registered	S5	None
Weldep xr 150 EACH TABLET CONTAINS: BUPROPION HCL EQUIVALENT TO BUPROPION 150,0 mg	150	480112.11448/1.2/0112.114	Registered	S5	None
Weldep xr 300 EACH TABLET CONTAINS: BUPROPION HCL EQUIVALENT TO BUPROPION 300,0 mg	300	480113.11548/1.2/0113.115	Registered	S5	None
Budep xr 150 Each Tablet contains: Bupropion HCL equivalent to Bupropion 150,0 mg	150	48011448/1.2/0114	Registered	S5	None
Budep xr 300 Each Tablet contains: Bupropion HCL equivalent to Bupropion 300,0 mg	300	48011548/1.2/0115	Registered	S5	None
Bupropion xr 150 adco	150 mg.Extended-release tablets.	500967.06550/1.2/0967.965Approved 7 June 2023	Registered	S5	PI PIL
Prodyna 150 MG xr EACH TABLET CONTAINS BUPROPION HYDROCHLORIDE 150,0 mg	150 mg	54018154/1.2/0181	Registered	S5	None
Prodyna 300 MG xr EACH TABLET CONTAINS BUPROPION HYDROCHLORIDE 300,0 mg	300 mg	54018254/1.2/0182	Registered	S5	None
Bupropion 150 MG xr DYNA EACH TABLET CONTAINS BUPROPION HYDROCHLORIDE 150,0 mg	150 mg	540183.18154/1.2/0183.181	Cancelled	S5	None
Bupropion 300 MG xr DYNA EACH TABLET CONTAINS BUPROPION HYDROCHLORIDE 300,0 mg	300 mg	540184.18254/1.2/0184.182	Cancelled	S5	None
Bupropion 300 accord EACH TABLET CONTAINS:BUPROPION HYDROCHLORIDE 300,0 mg	300 mgTablet	55077855/1.2/0778Approved 25 April 2025	Registered	S5	PI PIL
Bupropion 150xl DRL EACH TABLET CONTAINS BUPROPION HYDROCHLORIDE 150,0 mg	Not listed	56029256/1.2/0292	Registered	S5	None
Bupropion 300 xl DRL EACH TABLET CONTAINS BUPROPION HYDROCHLORIDE 300,0 mg	300	56029356/1.2/0293	Registered	S5	None
Bupropion xl150 MG AURO EACH TABLET CONTAINS BUPROPION HYDROCHLORIDE 150,0 mg	150 mg	56075156/1.2/0751	Registered	S5	None
Bupropion xl 300 MG AURO EACH TABLET CONTAINS BUPROPION HYDROCHLORIDE 300,0 mg	300 mg	56075256/1.2/0752	Registered	S5	None
Genipron xl 150 MG EACH TABLET CONTAINS BUPROPION HYDROCHLORIDE 150,0 mg	150 mg	560753.75156/1.2/0753.751	Registered	S5	None
Genipron xl 300 MG EACH TABLET CONTAINS BUPROPION HYDROCHLORIDE 300,0 mg	300 mg	560754.75256/1.2/0754.752	Registered	S5	None

Regulatory status

Where S5 sits on the scale

S0S1S2S3S4S5S6S7S8

Prescription-only, with tighter controls on repeats.

Schedule 5 medicines need a prescription, and repeat dispensing is capped at six months in total; the prescriber must state upfront how many times, and at what intervals, it may be repeated. Extra limits apply to some uses: if it is being used for its anxiolytic, antidepressant, tranquillising or analgesic properties, it cannot be prescribed for longer than six months without a further consultation. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S5, read from the product's PI-PIL leaflet.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it.

Consolidated Schedules listings for Bupropion

S5: Bupropion
Consolidated Schedules 06 July 2026, line 9290

Pharmacological class: Psychoanaleptics (antidepressants). (class 1.2)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Schedule verified from official documents

Schedule Verification

Wellbutrin xl 150, Glaxosmithkline South Africa (Pty) Limited is scheduled S5 in its official SAHPRA documents, read with 90% confidence.

Professional information (PI)For healthcare professionalsWellbutrin xl 150, Glaxosmithkline South Africa (Pty) Limited Patient information leaflet (PIL)For patients and carersWellbutrin xl 150, Glaxosmithkline South Africa (Pty) Limited

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles

Background